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Abstract: INTRODUCTION: The development of a clinical guideline is a challenging process. National
and international organizations have established a variety of approaches, grading systems, evaluation
scales and voting modes, however a practical description which illustrates all steps from starting the
initiative to publication and dissemination of the guideline is usually not provided. We describe a struc-
tured guideline procedure that can be adjusted to the requirements of other multinational guidelines.
METHODS: Clinical scientists with experience of organizing and contributing to guidelines initiated this
guideline project. A balance between scientific evidence and clinical experience was achieved by involving
European specialist societies and physicians from 18 European countries. For persons contributing to
the guideline process, different levels of involvement were defined. The tasks were assigned to different
groups of persons, which formed scientific institutions. RESULTS: We describe organizational structures
and institutions, a stepwise approach to tasks, and illustrate the multistep guideline development pro-
cedure in a flowchart diagram that shows the workflow and the assigned responsibilities and provides
further details for the execution of each step, including timelines. The process is split into 4 phases:
Foundation, Preparation, Voting and Publication. DISCUSSION: This structured procedure can serve
as a blueprint for future multinational initiatives and may also aid future attempts to standardize and
harmonize the guideline development processes. Although the described structured procedure is for a
diagnostic guideline, it may also be appropriate for therapeutic guidelines by adjusting the acceptance
criteria for statements and recommendations.
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Introduction: The development of a clinical guideline is a challenging process. National and 29 
international organizations have established a variety of approaches, grading systems, evaluation 30 
scales and voting modes, however a practical description which illustrates all steps from starting the 31 
initiative to publication and dissemination of the guideline is usually not provided. We describe a 32 
structured guideline procedure that can be adjusted to the requirements of other guidelines.  33 
Methods: Clinical scientists with experience of organizing and contributing to guidelines initiated this 34 
guideline project.  A balance between scientific evidence and clinical experience was achieved by 35 
involving representatives of European specialist societies and physicians from 18 European countries. 36 
For persons contributing to the guideline process, different levels of involvement were defined. The 37 
tasks were assigned to different groups of persons, which formed scientific institutions. 38 
Results: We describe organizational structures and institutions, a stepwise approach to tasks, and 39 
illustrate the multistep guideline development procedure in a flowchart diagram that shows the 40 
workflow and the assigned responsibilities and provides further details for the execution of each 41 
step, including timelines. The process is split into 4 phases: Foundation, Preparation, Voting and 42 
Publication.  43 
Discussion: This structured procedure can serve as a blueprint for future initiatives and may also aid 44 
future attempts to standardize and harmonize the guideline development processes. Although the 45 
described structured procedure is for a diagnostic guideline, it may also be appropriate for 46 
therapeutic guidelines by adjusting the acceptance criteria for statements and recommendations. 47 
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Guidelines are an important tool for improvement and harmonization of clinical decision making that 75 
have the potential to improve patients’ outcomes. (1) Guidelines may be classified as “evidence 76 
based”, having been developed after a systematic research and evaluation of literature, such as the 77 
German S2e guidelines, or as “consensus based”, having been developed by a representative group 78 
of experts using an structured consensus process, such as the German S2k guidelines. (2) Evidence 79 
based guidelines (3) may seem preferable because of higher scientific rigor, however they require a 80 
large base of scientifically sound and valid evidence. For clinically relevant topics for which such high 81 
quality evidence is not available consensus based guidelines (4) may serve to summarize current 82 
knowledge and harmonize clinical practice, and to set the agenda for future research.  83 
For clinical practice guidelines, a consensus process is often used to evaluate and interpret the 84 
evidence in the context of the patient’s and the doctor’s values and preferences. (5,6) This can be a 85 
challenging process. National and international organizations have established a variety of different 86 
approaches, grading systems, evaluation scales and voting modes for the development of new 87 
guidelines, these include the AGREE II, DELBI, GRADE, SIGN, CEBM, Delphi Methods.  (5–12). 88 
Recently, the Guidelines International Network identified 11 key components for guideline 89 
development, including composition of the guideline development group, decision making process, 90 
methods, evidence review and rating. (14) These recommendations are helpful on many levels; 91 
however, a practical description of these procedures illustrating all steps from starting the initiative 92 
to publication and dissemination of the guideline was not provided. In April 2019 the authors (HFH, 93 
MF, JK) initiated a multi-society / multinational European guideline for indications, performance and 94 
clinical impact of H2- and 13C-breath tests in adult and pediatric patients. By studying recent 95 
guidelines (15–19) and guided by the requirements set out by United European Gastroenterology 96 
(UEG) for grant support, a procedure which fitted the aims of this guideline was developed. Along the 97 
way challenges were encountered, plans were adapted, and a lot was learned about this process, 98 
including the pros and cons of different approaches and the timelines encountered.  99 
This manuscript will share the experience that the authors learned during this process, with a focus 100 
on points that are generalizable to the development of other guidelines. A structured description of 101 
the guideline procedure is provided that can be adjusted to the requirements of other clinical 102 
practice guidelines. This blueprint may also aid future attempts to standardize and harmonize the 103 
guideline development processes. 104 
 105 





The guideline project was initiated by clinical scientists with experience of the use of breath tests in 108 
clinical medicine and the research setting (20–31) and that have organized or contributed to other 109 
national and international guidelines. (19,32–43) A key aim was to provide a balance between the 110 
scientific evidence and the collective experience from experts working in medical systems in different 111 
European countries with a wide range of health-economic circumstances. To serve this purpose, the 112 
authors identified and obtained the endorsement of UEG member societies with a major interest in 113 
the topics of the guideline (EAGEN, ESNM and ESPGHAN), enlisted national societies representing 114 
different European regions (Austria, Bulgaria, Germany, Hungary, Italy, Switzerland, Romania and the 115 
United Kingdom) and collaborated with the UEG-Guideline initiative (44). In order to define and 116 
assign responsibilities throughout the guideline process the following scientific institutions where 117 
defined: 118 
Heads of Guideline (HG): Three authors of this paper (HFH, MF, JK) initiated, obtained funding, 119 
coordinated, managed and supervised the guideline development process. 120 
Core Group Leads (CGL): Seven experts (including the HG) were selected by the HG and / or 121 
nominated by scientific societies based on their experience and publications in the field. The CGL 122 
prepared a list of topics (main topics and subtopics) to be covered by the guideline. One of the CGL 123 
led each of the main topics. The CGL also defined the overall guideline process, grading system, 124 
evaluation scale and acceptance criteria and will lead the writing of the final manuscript. 125 
Core Group (CG): 23 experts (including the CGL) were selected by the CGL and participating societies. 126 
The CG was composed of members from participating societies as well as experts with publications in 127 
the field and experience in guideline projects. Special consideration was given to representation of 128 
gender and age. The CG played a central role for the guideline development process. The key tasks 129 
were the development of statements and recommendations and their revision/modification after 130 
voting rounds as well as the review of drafts of the manuscript. For this purpose, the members of the 131 
CG were assigned, according to their personal interests, to specific topics of the guideline. 132 
Reviewers (Re): Within a period of 3 months HG, CGL and CG recruited 22 professionals to serve as 133 
reviewers through calls to contributing societies and personal contacts. In total, 45 persons from 18 134 
European countries were involved in the review process. Three rounds of a Delphi-voting process 135 
were planned with all those involved in the process encouraged to comment on statements and 136 
recommendations. Figure 1 shows the regional distribution of all participating persons. 137 
Guideline Office (GO): The administrative work of the guideline office (MS, HFH) included 138 
management of the budget and costs related to work meetings, travel expenses and publications 139 
fees. In addition, it managed organizational matters including declarations of conflicts of interest and 140 
communication with supporting organizations. The GO was also responsible for literature search, 141 
information management, and preparation of voting, collection and consolidation of voting results 142 





The development of a guideline is a multistep process. In order to illustrate the procedure in a 145 
comprehensible manner, we use a flowchart diagram that shows the workflow and the assigned 146 
responsibilities and provides further details for the execution. The responsibility column lists the 147 
involved institutions and indicates assignment of tasks with an “x”. These institutions are Heads of 148 
Guideline (HG), Core Group Leads (CGL), Core Group (CG), Reviewers (Re) and Guideline Office (GO). 149 
The workflow column visualizes work steps (rectangles) and decision points (rhombus). An arrow 150 
represents tasks that are work in progress and executed parallel to other steps. Further explanations 151 
of each work step and decision point are provided in the details column. The procedure is split into 4 152 
phases: Foundation, Preparation, Voting and Publication.  153 
 154 
Phase 1: Foundation (Fig. 2a) 155 
 156 
Phase 1 covered the foundation of the guideline development process from an organizational 157 
perspective. It comprised initiation of the development process, establishing basic requirements and 158 
formation of essential institutions. The development process started with an initiative of the HG, 159 
who discussed and identified the need for a guideline. The need for an updated guideline may be 160 
due to recent changes in knowledge or spread of application into uses or health care environments, 161 
which go beyond initially considered, specific clinical applications or health care environments. The 162 
key task of this step is review of literature and guidelines related to the topic, which is of 163 
fundamental importance for the justification of the whole process. After the idea for a new guideline 164 
was conceived, the HG needed to identify stakeholders and interest groups to back up the initiative. 165 
To provide the depth of knowledge and scientific expertise required, experts, characterized by 166 
important publications in the field, and / or position on the committees of international scientific 167 
societies were identified. Wide regional representation was achieved by involving local opinion 168 
leaders nominated by national societies. This ensured the guidelines were relevant to different 169 
clinical environments, clinical approaches and health-economic backgrounds with the aim to 170 
minimize disparities between health care systems across a large geographic area, which is a key aim 171 
of the UEG Guideline initiative that supported this project. At this stage, the HG also needed to 172 
secure financing of the guideline process. First, a budget with the expected cost for scientific staff 173 
and office personnel, work meetings, travel expenses and publication had to be developed. 174 
Subsequently the HG filed an application for a grant from UEG. Securing financing was completed by 175 
the end of phase 1 and was the prerequisite to advance to phase 2. Once finance was secured, HG 176 
set up the Guideline Office (GO) for administrative and scientific purposes. In cooperation with the 177 
Core Group Leads, the HG established the Core Group and assigned CGL to main topics of the 178 
guideline. A prespecified time schedule is a prerequisite for funding and for communication and 179 
cooperation with interest groups. Therefore, the HG and CGL developed a timeline using a Gantt 180 
Chart. However, flexibility of schedules was allowed in case of delays or developments. At this point 181 
Phase 1 was completed. The time course for the foundation phase of a guideline development 182 
process depends on various external factors that are not under control of HG - e.g. discussions with 183 





Phase 2: Preparation (Fig. 2b) 186 
 187 
After completing the foundation phase and having laid the groundwork by establishing necessary 188 
institutions, the guideline development process entered phase 2, which focuses on preparation for 189 
the voting process. At the beginning of phase 2, the HG and CGL started with the invitation of 190 
reviewers for the Delphi process. Interested experts were identified and selected by participating 191 
interest groups, HG and CGL through personal contacts. Special attention was paid to a pan-192 
European regional spread of reviewers as shown in Figure 1. After the invitation of reviewers had 193 
been initiated, the HG and CGL defined the guideline process in detail. This included specification of 194 
working structure and further procedure for the CG, definition of statements and recommendations 195 
including the grading system for recommendations and selection of voting mode with respective 196 
evaluation scale and acceptance criteria. The grading of recommendations was derived from the 197 
quality of evidence as assessed by Oxford Grading (11) and strength of recommendations was 198 
clarified by the wording used (Appendix Table 1). As for the voting mode, a three round Delphi 199 
process with digital voting sheets was selected. This facilitated the involvement of reviewers from all 200 
over Europe and allowed for voting to remain anonymous for all participants (details were known to 201 
GO), which was considered crucial to assure an unbiased and representative vote. For the 202 
assessment of agreement level, a 6-point Likert scale - reaching from “A+ agree strongly” to “D+ 203 
disagree strongly” - was used in the voting on statements and recommendations (Appendix Table 2). 204 
The acceptance criteria were defined as shown in Appendix Table 3. Statements and 205 
recommendations were accepted if they reached ≥80% of agreement (A+ or A) and <10% of 206 
disagreement (D+ or D) in Delphi voting. Next, the HG and CGL defined topics for the guideline by 207 
defining key questions to be answered by the guideline and by drawing up a list of main topics and 208 
subtopics to be covered by the guideline. As shown in Appendix Table 4, members of the CG were 209 
assigned to guideline topics according to their interests and the CGL were appointed to chair these 210 
topic groups. As the next step, the scientific GO implemented the information management for the 211 
process. Relevant publications for the development of statements and recommendations were 212 
identified by a systematic literature search (PICO) (45) and additional literature was collected from 213 
members of the CG. To facilitate information exchange and to allow easy access to the literature for 214 
all members of the guideline project, a cloud-based file sharing platform was set up. Members of the 215 
CG were enabled to upload and to read files, whereas reviewers were only permitted to read. Based 216 
on the identified literature, the CG and corresponding CGL developed statements and 217 
recommendations for their respective topics. This included assigning strength to statements and 218 
recommendations, as well as provisional grading of recommendations in accordance with the 219 
predetermined definition. The final version of statements and recommendations of each main topic 220 
were sent to the scientific GO and were used to prepare the Delphi process. The GO collected and 221 
consolidated all proposed statements and recommendations and prepared spreadsheets for the 222 
Delphi voting. These spreadsheets included instructions on the voting process, the statements and 223 
recommendations with corresponding strength and grading, the 6-point Likert scale for evaluation 224 
and space for comments. An example of a spreadsheet for the Delphi voting is provided in Appendix 225 





Phase 3: Voting (Fig. 2c) 228 
 229 
In phase 3, the Delphi voting took place. In total three Delphi rounds were conducted to reach a 230 
consensus on statements and recommendations. Hereinafter the first Delphi round is described in 231 
detail (representative of all three rounds). In addition, a detailed illustration of the voting process 232 
with focus on interactions between participating institutions is shown in the “swimlane” diagram in 233 
Figure 3.  The 1st Delphi round started with the GO sending out a mail with the spreadsheets for the 234 
Delphi voting to all reviewers. The spreadsheet contained instructions for the voting process and the 235 
request to response within a period of 3 weeks. Reviewers were asked to vote on statements and 236 
recommendations according to the predefined evaluation scale and to provide comments. Twice 237 
weekly updates about the progress of the voting process, supplemented towards the end of the 3-238 
week period by “friendly reminders” of schedule were sent to the reviewers by e-Mail by the GO and 239 
HG to assure compliance with the deadline. This included a running total of the number of responses 240 
received. Completed forms were sent back by e-mail to the GO, which was responsible for the 241 
collection of voting results. All replies were consolidated by preparing a spreadsheet with all results 242 
and comments. Then the GO and HG defined five groups of statements and recommendations based 243 
on the predefined acceptance criteria:  244 
a.  “Accepted” according to the predefined criteria and no need for modification and further 245 
voting. 246 
b.  “Accepted” according to the predefined criteria with comments by reviewers which resulted 247 
in minor editorial modifications of the statement or recommendation by the GO and HG, not 248 
requiring revoting. 249 
c. “Accepted” according to the predefined criteria with comments by reviewers which resulted 250 
in major modifications by the GO and HG requiring revoting in the next Delphi round. 251 
d. “Not accepted” according to predefined criteria and considered to be likely by HG that a 252 
modification according to reviewers’ comments may result in acceptance in the next Delphi 253 
round. 254 
e. “Not accepted” and considered unlikely by HG that modifications will result in acceptance in 255 
the next Delphi round.  256 
Statements and recommendations in groups a. and b. where consolidated in a separate spread sheet 257 
of “Accepted” with respective strengths, gradings and condensed voting results. Statements and 258 
recommendations in group e. were collected in a file “Not Accepted” with condensed voting results. 259 
These statements and recommendations will be reported in the final guideline manuscript as not 260 
having achieved consensus. Statements and recommendations in groups c. and d. where sent to the 261 
respective CGL with the request to modify them in cooperation with the members of their respective 262 
CG. These revised statements and recommendations entered the next Delphi round. This process 263 
took 6.5 weeks. Preparation and execution of the next Delphi rounds were performed in accordance 264 
to the 1st Delphi round. Due to the decreasing number of statements and recommendations that 265 
required voting, the 2nd and 3rd Delphi round only took 2 weeks each, with revision of statements 266 




statements and recommendations (a. and b. according to the list) to the spreadsheet “Accepted”. If 268 
after three Delphi rounds and revisions some statements and recommendations still were not 269 
accepted, they were added to group e.  270 
 271 
Phase 4: Publication and Post-Publication (shown in Fig. 2d) 272 
 273 
After completion of the Delphi voting, the project will enter the final stage of the development 274 
process: publication. The list of the final statements and recommendations for the new guideline 275 
will be sent to the HG and CGL for revision on grading in accordance to the predefined grading 276 
criteria. Following this, the HG and the CGL will prepare the manuscript for the guideline. Following 277 
publication of a clinical practice guideline the information shall be disseminated as widely as possible 278 
with the aim of improving medical care and identifying areas of research needs wherever these tests 279 
are applied. Dissemination may include translation into various European languages to facilitate local 280 
adoption, presentation at national and international meetings, classroom teaching and video clips on 281 







Clinical Practice Guidelines assist physicians and provide them with the information required to 286 
deliver high quality care and / or to communicate the best care options to patients. (44) In a 287 
consensus process, the best available evidence is evaluated and interpreted in the context of the 288 
patient’s and the doctor’s values and preferences (5,6), taking account of local facilities and health 289 
care environments. The path to a new guideline can be challenging. Previous publications have 290 
recommended different approaches; (2,7–12) however, practical descriptions of guideline processes 291 
are lacking. This paper describes the structured procedure used to develop a multinational guideline. 292 
It is hoped that this can serve as a blueprint for future initiatives.  293 
We describe organizational structures and institutions, a stepwise approach to tasks and the 294 
responsibilities assigned to contributors to the guideline process. In addition, time management is of 295 
great importance. Criteria for application for financial support usually require a description of the 296 
schedule of activities, for example using a Gantt chart. However, flexibility of timelines, especially in 297 
phase 2 of the guideline process (shown in Fig. 2b) is of fundamental importance for successful 298 
project management. Originally a duration of 14 weeks was scheduled for this step, whereas finally it 299 
took over 20 weeks.  However, some of the additional time spent in phase 2 for the development 300 
and refinement of statements and recommendations and of grading of quality and strength was 301 
recovered in phase 3, when results of Delphi voting where better than expected and therefore 302 
decreased the time needed for rewording and preparation of the next Delphi round (and presumably 303 
also the time required for drafting the manuscript). Phase 3 was within the projected time course for 304 
which twice weekly updates and reminders of the reviewers we considered essential. Within the 305 
time span assigned for Delphi voting, the majority of responses were sent to the GO in the last days 306 
before the voting was closed. A total number of 167 statements and recommendations were sent to 307 
45 reviewers in the 1st Delphi voting. During the 1st voting round we experienced a high rate of 308 
acceptance and the large majority of 138 statements and recommendations fulfilled the criteria. 309 
After revision and rephrasing, 28 statements or recommendations were voted on in a 2nd Delphi 310 
round, with 20 of these items meeting the acceptance criteria. Finally, there were only 6 statements 311 
and recommendations that required a 3rd Delphi round. During the process 17 statements were 312 
removed from voting and either moved to group e or were replaced by new statements or 313 
recommendations.  314 
A key challenge in the development of any consensus-based guideline is to consider both the results 315 
of research studies (the evidence base) and a democratic vote representing diverse clinical practice 316 
and experience in a wide range of health care environments. Many aspects of clinical medicine have 317 
not been subjected to rigorous investigation. Established practice is not always evidence based and 318 
sometimes based on unproven assumptions. Indeed, with regards to breath testing, for example 319 
fructose breath testing, it can be argued that the evidence base is scarce and contradictory so that 320 
this test should not be performed at all. (46) However, some methods and some tests are so well 321 
established in clinical practice that this is not a position that can be accepted by the majority of 322 
practitioners and therefore these techniques should not be excluded from a consensus clinical 323 
guideline. It is important not to throw out the baby with the bathwater! A balance between the 324 
weight of evidence, the expertise of leading scientists, and the results of the Delphi voting process 325 




of clinical circumstances has to be found. On this basis, to ensure that consensus was achieved, the 327 
CG considered it necessary to compromise, to accept that the majority position was not always 328 
“evidence based”, find a level of agreement, and to formulate statements and recommendations 329 
that acknowledged the “absence of evidence” but provided clear guidance based on clinical 330 
experience. We consider that this approach is justified if it helps to ensure that guidelines are widely 331 
adopted and that tests are performed, analysed and interpreted to consistent standards. Incremental 332 
change to practice is the aim. Especially in version 1.0 of any guideline, it is essential that the 333 
opportunity is taken to discuss the evidence for and against current practice as outlined in the 334 
statements and recommendations. By highlighting where there is missing (or even contradictory) 335 
evidence, guidelines can set the agenda for future research, the results of which will inform the next 336 
iteration of the guideline.  337 
Clearly the structured procedure outlined in this paper will not be appropriate for the development 338 
of all guidelines. The approach described here was for a diagnostic guideline. Although a similar 339 
approach may be appropriate for therapeutic guidelines, acceptance criteria for statements and 340 
recommendations are often higher in this setting, than the 80% threshold used in our Delphi process. 341 
Moreover, careful assessment of comments made by individual reviewers with modification of 342 
recommendations or statements can be constructive even if the minimum agreement level has been 343 
reached. This flexibility can help to achieve very high levels of consensus and ensure optimal uptake 344 
of recommendations in clinical practice.  345 
One aspect of guideline development that is not covered in our structured approach to guideline 346 
development is Patient and Public Involvement (PPI). Successful guidelines that have a positive 347 
impact on clinical practice are generally simple, easy to apply and consistent with the values and 348 
preferences of those delivering and receiving medical care. Ideally patient representatives would be 349 
involved at every stage; however, this was not planned in this instance. Instead, after publication of 350 
the European Guideline for indications, performance and clinical impact of H2- and 13C-breath tests in 351 
adult and pediatric patients a qualitative and quantitative assessment of guideline adoption into 352 
clinical practice is planned. This will not only include feedback from doctors and other health care 353 
professionals but also from patients referred for breath test investigation. It is relatively easy to 354 
assess whether the guidelines are adopted and adhered to. However, publication of a new guideline 355 
also represents an opportunity to better understand the reasons why such tests are performed and 356 
also whether the expectations of all those involved are fulfilled by the investigation. This will inform 357 
the development of future breath test protocols and the next iteration of the guideline, with the aim 358 
that this technology will address ever more closely the needs and wants of doctors and their 359 
patients.  360 
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